JUND Promotes Tumorigenesis via Specifically Binding on Enhancers of Multiple Oncogenes in Cervical Cancer

References

• Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet. 2019;393(10167):169–182. doi:10.1016/S0140-6736(18)32470-X
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus and cervical cancer. Lancet. 2013;382(9895):889–899. doi:10.1016/S0140-6736(13)60022-7
   PubMed Web of Science ®Google Scholar
• Small WJ, Bacon MA, Bajaj A, et al. Cervical cancer: a global health crisis. Cancer-Am Cancer Soc. 2017;123(13):2404–2412.
   Google Scholar
• Fang J, Zhang H, Jin S. Epigenetics and cervical cancer: from pathogenesis to therapy. Tumour Biol. 2014;35(6):5083–5093. doi:10.1007/s13277-014-1737-z
   PubMedGoogle Scholar
• Spitz F, Furlong EE. Transcription factors: from enhancer binding to developmental control. Nat Rev Genet. 2012;13(9):613–626. doi:10.1038/nrg3207
   PubMed Web of Science ®Google Scholar
• Hnisz D, Abraham BJ, Lee TI, et al. Super-enhancers in the control of cell identity and disease. Cell. 2013;155(4):934–947. doi:10.1016/j.cell.2013.09.053
   PubMed Web of Science ®Google Scholar
• Zhou J, Wang D, Tang D, Huang W. Abnormal activations of super-enhancers enhance the carcinogenicity in lung adenocarcinoma. Cancer Manag Res. 2020;12:8509–8518. doi:10.2147/CMAR.S258497
   PubMed Web of Science ®Google Scholar
• Hu CY, Mohtat D, Yu Y, et al. Kidney cancer is characterized by aberrant methylation of tissue-specific enhancers that are prognostic for overall survival. Clin Cancer Res. 2014;20(16):4349–4360. doi:10.1158/1078-0432.CCR-14-0494
   PubMed Web of Science ®Google Scholar
• Deng W, Blobel GA. Detecting long-range enhancer-promoter interactions by quantitative chromosome conformation capture. Methods Mol Biol. 2017;1468:51–62.
   PubMedGoogle Scholar
• Calo E, Wysocka J. Modification of enhancer chromatin: what, how, and why? Mol Cell. 2013;49(5):825–837. doi:10.1016/j.molcel.2013.01.038
   PubMed Web of Science ®Google Scholar
• Barutcu AR, Fritz AJ, Zaidi SK, et al. C-ing the genome: a compendium of chromosome conformation capture methods to study higher-order chromatin organization. J Cell Physiol. 2016;231(1):31–35. doi:10.1002/jcp.25062
   PubMed Web of Science ®Google Scholar
• Wang C, Zou H, Chen A, et al. C-Myc-activated long non-coding RNA PVT1 enhances the proliferation of cervical cancer cells by sponging miR-486-3p. J Biochem. 2020;167(6):565–575. doi:10.1093/jb/mvaa005
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Integrated genomic and molecular characterization of cervical cancer. Nature. 2017;543(7645):378–384. doi:10.1038/nature21386
   PubMed Web of Science ®Google Scholar
• Palstra RJ, Grosveld F. Transcription factor binding at enhancers: shaping a genomic regulatory landscape in flux. Front Genet. 2012;3:195. doi:10.3389/fgene.2012.00195
   PubMedGoogle Scholar
• Hamdan FH, Johnsen SA. Perturbing enhancer activity in cancer therapy. Cancers. 2019;11:5. doi:10.3390/cancers11050634
   Web of Science ®Google Scholar
• Elliott B, Millena AC, Matyunina L, et al. Essential role of JunD in cell proliferation is mediated via MYC signaling in prostate cancer cells. Cancer Lett. 2019;448:155–167. doi:10.1016/j.canlet.2019.02.005
   PubMed Web of Science ®Google Scholar
• Ishikawa C, Senba M, Mori N. Butein inhibits NF-kappaB, AP-1 and Akt activation in adult T-cell leukemia/lymphoma. Int J Oncol. 2017;51(2):633–643. doi:10.3892/ijo.2017.4026
   PubMed Web of Science ®Google Scholar
• Cheng BY, Lau EY, Leung HW, et al. IRAK1 augments cancer stemness and drug resistance via the AP-1/AKR1B10 signaling cascade in hepatocellular carcinoma. Cancer Res. 2018;78(9):2332–2342. doi:10.1158/0008-5472.CAN-17-2445
   PubMed Web of Science ®Google Scholar
• Kajanne R, Miettinen P, Tenhunen M, Leppa S. Transcription factor AP-1 promotes growth and radioresistance in prostate cancer cells. Int J Oncol. 2009;35(5):1175–1182. doi:10.3892/ijo_00000434
   PubMed Web of Science ®Google Scholar
• Millena AC, Vo BT, Khan SA. JunD is required for proliferation of prostate cancer cells and plays a role in transforming growth factor-beta (TGF-beta)-induced inhibition of cell proliferation. J Biol Chem. 2016;291(34):17964–17976. doi:10.1074/jbc.M116.714899
   PubMed Web of Science ®Google Scholar
• Nees M, Geoghegan JM, Hyman T, Frank S, Miller L, Woodworth CD. Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. J Virol. 2001;75(9):4283–4296. doi:10.1128/JVI.75.9.4283-4296.2001
   PubMed Web of Science ®Google Scholar
• Li G, Chen Y, Snyder MP, Zhang MQ. ChIA-PET2: a versatile and flexible pipeline for ChIA-PET data analysis. Nucleic Acids Res. 2017;45(1):e4. doi:10.1093/nar/gkw809
   PubMed Web of Science ®Google Scholar
• Pope BD, Ryba T, Dileep V, et al. Topologically associating domains are stable units of replication-timing regulation. Nature. 2014;515(7527):402–405. doi:10.1038/nature13986
   PubMed Web of Science ®Google Scholar
• den Boon JA, Pyeon D, Wang SS, et al. Molecular transitions from papillomavirus infection to cervical precancer and cancer: role of stromal estrogen receptor signaling. Proc Natl Acad Sci U S A. 2015;112(25):E3255–E3264. doi:10.1073/pnas.1509322112
   PubMed Web of Science ®Google Scholar
• Marrero-Rodriguez D, la Cruz HA, Taniguchi-Ponciano K, et al. Kruppel like factors family expression in cervical cancer cells. Arch Med Res. 2017;48(4):314–322. doi:10.1016/j.arcmed.2017.06.011
   PubMed Web of Science ®Google Scholar
• Bailey TL, Boden M, Buske FA, et al. MEME SUITE: tools for motif discovery and searching. Nucleic Acids Res. 2009;37:W202–W208. doi:10.1093/nar/gkp335
   PubMed Web of Science ®Google Scholar
• Kulakovskiy IV, Medvedeva YA, Schaefer U, et al. HOCOMOCO: a comprehensive collection of human transcription factor binding sites models. Nucleic Acids Res. 2013;41:D195–D202. doi:10.1093/nar/gks1089
   PubMed Web of Science ®Google Scholar
• Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30(7):923–930. doi:10.1093/bioinformatics/btt656
   PubMed Web of Science ®Google Scholar
• Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. doi:10.1186/s13059-014-0550-8
   PubMed Web of Science ®Google Scholar
• Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57. doi:10.1038/nprot.2008.211
   PubMed Web of Science ®Google Scholar
• Selvaraj N, Budka JA, Ferris MW, Plotnik JP, Hollenhorst PC. Extracellular signal-regulated kinase signaling regulates the opposing roles of JUN family transcription factors at ETS/AP-1 sites and in cell migration. Mol Cell Biol. 2015;35(1):88–100. doi:10.1128/MCB.00982-14
   PubMed Web of Science ®Google Scholar
• Chen H, Liu H, Qing G. Targeting oncogenic Myc as a strategy for cancer treatment. Signal Transduct Target Ther. 2018;3:5. doi:10.1038/s41392-018-0008-7
   PubMed Web of Science ®Google Scholar
• Dang CV. MYC on the path to cancer. Cell. 2012;149(1):22–35. doi:10.1016/j.cell.2012.03.003
   PubMed Web of Science ®Google Scholar
• Trop-Steinberg S, Azar Y. AP-1 expression and its clinical relevance in immune disorders and cancer. Am J Med Sci. 2017;353(5):474–483. doi:10.1016/j.amjms.2017.01.019
   PubMed Web of Science ®Google Scholar
• Alves DS, Mapekula L, Mdletshe N, Chetty D, Mowla S. HIV-1 transactivator of transcription (Tat) Co-operates With AP-1 factors to enhance c-MYC Transcription. Front Cell Dev Biol. 2021;9:693706. doi:10.3389/fcell.2021.693706
   PubMed Web of Science ®Google Scholar
• Wang C, Mayer JA, Mazumdar A, et al. Estrogen induces c-myc gene expression via an upstream enhancer activated by the estrogen receptor and the AP-1 transcription factor. Mol Endocrinol. 2011;25(9):1527–1538. doi:10.1210/me.2011-1037
   PubMedGoogle Scholar
• Lin SH, Wang HK, Yeh KT, et al. c-MYC expression in T (III/IV) stage oral squamous cell carcinoma (OSCC) patients. Cancer Manag Res. 2019;11:5163–5169. doi:10.2147/CMAR.S201943
   PubMed Web of Science ®Google Scholar
• Spender LC, Inman GJ. Developments in Burkitt’s lymphoma: novel cooperations in oncogenic MYC signaling. Cancer Manag Res. 2014;6:27–38. doi:10.2147/CMAR.S37745
   PubMed Web of Science ®Google Scholar
• Edwards J, Krishna NS, Mukherjee R, Bartlett JM. The role of c-Jun and c-Fos expression in androgen-independent prostate cancer. J Pathol. 2004;204(2):153–158. doi:10.1002/path.1605
   PubMed Web of Science ®Google Scholar